IL138979A0 - Use of cannabinoids as anti-inflammatory agents - Google Patents

Use of cannabinoids as anti-inflammatory agents

Info

Publication number
IL138979A0
IL138979A0 IL13897999A IL13897999A IL138979A0 IL 138979 A0 IL138979 A0 IL 138979A0 IL 13897999 A IL13897999 A IL 13897999A IL 13897999 A IL13897999 A IL 13897999A IL 138979 A0 IL138979 A0 IL 138979A0
Authority
IL
Israel
Prior art keywords
cannabinoids
inflammatory agents
inflammatory diseases
treating inflammatory
cannabidiol
Prior art date
Application number
IL13897999A
Other languages
English (en)
Original Assignee
Mathilda & Terrence Kennedy In
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mathilda & Terrence Kennedy In, Yissum Res Dev Co filed Critical Mathilda & Terrence Kennedy In
Publication of IL138979A0 publication Critical patent/IL138979A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13897999A 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents IL138979A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents
PCT/GB1999/001140 WO1999052524A1 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
IL138979A0 true IL138979A0 (en) 2001-11-25

Family

ID=10830115

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13897999A IL138979A0 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Country Status (12)

Country Link
US (1) US6410588B1 (de)
EP (1) EP1071417B1 (de)
JP (1) JP2002511411A (de)
AT (1) ATE288749T1 (de)
AU (1) AU757945B2 (de)
CA (1) CA2328368C (de)
DE (1) DE69923671T2 (de)
DK (1) DK1071417T3 (de)
ES (1) ES2241277T3 (de)
GB (1) GB9807639D0 (de)
IL (1) IL138979A0 (de)
WO (1) WO1999052524A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
BR0009200A (pt) 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
EP1206934A1 (de) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blockade von Natriumkanälen mit Phenolderivaten
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
EP1482917B1 (de) * 2002-02-01 2019-05-08 GW Pharma Limited Zusammensetzungen mit cannabidiolsäure zur behandlung von übelkeit, erbrechen, emesis, reisekrankheit oder ähnlichen zuständen
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
SI1542657T1 (sl) * 2002-08-14 2012-04-30 Gw Pharma Ltd Kanabinoidne kapljevite formulacije za sluzniäśno administracijo
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
WO2006024958A2 (en) * 2004-08-09 2006-03-09 Novimmune S.A. Cannabinoid compositions and methods of use thereof
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20100158973A1 (en) 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US9956182B2 (en) 2013-05-02 2018-05-01 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease
US9889100B2 (en) 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
EP3277260B1 (de) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Pflanzenextrakte aus erodium crassifolium l'her und verwendungen davon
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017066747A1 (en) * 2015-10-16 2017-04-20 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
WO2017160923A1 (en) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations of argan oil and cannabidiol
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
WO2018064654A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
EP3534893A1 (de) 2016-11-02 2019-09-11 To Pharmaceuticals LLC Kombinationstherapie von cbd und copaxon
EP3592346A4 (de) 2017-03-05 2020-12-30 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) Zusammensetzungen und verfahren zur behandlung von krebs
WO2019014851A1 (zh) * 2017-07-18 2019-01-24 汉义生物科技（北京）有限公司 大麻二酚在治疗肺动脉高压中的应用
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods for treating degenerative joint disease with cannabidiol gel through the skin
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
EP3866781A4 (de) * 2018-10-16 2022-11-09 Systamedic Inc. Neuartige zusammensetzung zur behandlung von entzündlichen erkrankungen
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
AU2019424226B2 (en) * 2019-01-24 2023-06-29 Hanyi Bio-Technology Company Ltd. Use of geranylflavone A in preparation of drug for promoting healing of wounds
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
WO2020167751A1 (en) * 2019-02-11 2020-08-20 Chancey John Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, ormonosaccharide
WO2020223510A1 (en) * 2019-04-30 2020-11-05 Greenway Herbal Products, Llc Cannabinoid compositions and methods of using
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
AU2021250462A1 (en) * 2020-04-02 2022-12-01 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
IL298062A (en) * 2020-05-11 2023-01-01 Add Advanced Drug Delivery Tech Ltd Uses and formulations of cannabinoids
IL298059A (en) * 2020-05-11 2023-01-01 Add Advanced Drug Delivery Tech Ltd Uses and formulations of cannabinoids
CA3199891A1 (en) 2020-11-24 2022-06-02 Ruth Gallily Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
WO2023096918A1 (en) * 2021-11-27 2023-06-01 Miralogx Llc Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods
CA3244798A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa COMPOUNDS AND COMPOSITIONS AGAINST NEURODEGENERATIVE DISEASES
EP4230201A1 (de) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025259202A1 (en) * 2024-06-12 2025-12-18 Chiang Mai University A method of reprogramming human somatic cells and reprogrammed cells derived thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48824A (en) 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Also Published As

Publication number Publication date
ATE288749T1 (de) 2005-02-15
DE69923671T2 (de) 2006-03-16
AU3436199A (en) 1999-11-01
ES2241277T3 (es) 2005-10-16
CA2328368A1 (en) 1999-10-21
WO1999052524A1 (en) 1999-10-21
CA2328368C (en) 2009-03-31
DK1071417T3 (da) 2005-06-13
EP1071417A1 (de) 2001-01-31
AU757945B2 (en) 2003-03-13
GB9807639D0 (en) 1998-06-10
DE69923671D1 (de) 2005-03-17
US6410588B1 (en) 2002-06-25
JP2002511411A (ja) 2002-04-16
EP1071417B1 (de) 2005-02-09

Similar Documents

Publication Publication Date Title
GB9807639D0 (en) Anti-inflammatory agents
BR9910251A (pt) Estimulação hematopoiética
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
MY138883A (en) Use of asiatic acid for treatment of cencer
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
AU6178198A (en) Method of treating a tumor
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
GB9621630D0 (en) Treatment of skin disorders
CA2408541A1 (en) Treating eczema and/or psoriasis
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
BG101126A (en) The use of muramylpeptide compounds
DE69905602D1 (de) Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren
NO20012569L (no) Anvendelse av aryl-substituerte syklobutylalkylaminer for behandling av urininkontinens
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
IL139303A0 (en) Treatment of arthritis and other similar conditions
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
MD916G2 (ro) Unguent pentru tratamentul afecţiunilor dentare
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon
UA32281A (uk) Засіб "регенерин" для зовнішнього лікування гнійних ран і трофічних виразок

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired